The combination of 6-MF and immunotherapy reduced melanoma proliferative capacity, increased intracellular oxidative stress, and promoted, phosphorylation to inhibit the SLC7A11/GPX4 signaling pathway and promote ferroptosis in melanoma cells. This evidence concerns the gene GPX4 and melanoma.